Skip to content
Biophytis
LIVE HEALTHIER LONGER
Biophytis
  • Corporate
    • Executive Committee
    • Scientific Advisory Board
    • Boards of Directors
    • Code of Ethics
  • Our Science
    • BIO101
      • Posters & Publications
        • 2024
        • 2023
        • 2022
        • 2021
        • 2020
        • 2019
        • 2018
        • 2017
        • 2016
        • 2015
        • 2014
    • Macuneos (BIO201)
      • Posters & Publications
  • Pipeline
    • Pipeline
    • Key milestones in the development of BIO101
    • Sarcopenia: SARA clinical program
    • Obesity: OBA Clinical Program
    • COVID-19: COVA clinical program
    • Duchenne Muscular Dystrophy: MYODA clinical program
    • Age-related Macular Degeneration: MACA clinical program
  • Investors
    • Letter to shareholders
    • Live Stock Price
    • Corporate Presentation
    • General Meetings
      • 2024
      • 2023
      • 2022
      • 2021
      • 2020
    • AMF Regulated Information
    • SEC Filings
    • Financial Calendar
    • Convertible bonds
  • News
    • Press Releases
      • 2025
      • 2024
      • 2023
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
    • Biophytis in Media
  • Recruitment
  • Contact
    • Contact
    • Contact Information
    • Legal information
  • LinkedIn
  • Twitter
  • FR
  • EN
  • Corporate
    • Executive Committee
    • Scientific Advisory Board
    • Boards of Directors
    • Code of Ethics
  • Our Science
    • BIO101
      • Posters & Publications
        • 2024
        • 2023
        • 2022
        • 2021
        • 2020
        • 2019
        • 2018
        • 2017
        • 2016
        • 2015
        • 2014
    • Macuneos (BIO201)
      • Posters & Publications
  • Pipeline
    • Pipeline
    • Key milestones in the development of BIO101
    • Sarcopenia: SARA clinical program
    • Obesity: OBA Clinical Program
    • COVID-19: COVA clinical program
    • Duchenne Muscular Dystrophy: MYODA clinical program
    • Age-related Macular Degeneration: MACA clinical program
  • Investors
    • Letter to shareholders
    • Live Stock Price
    • Corporate Presentation
    • General Meetings
      • 2024
      • 2023
      • 2022
      • 2021
      • 2020
    • AMF Regulated Information
    • SEC Filings
    • Financial Calendar
    • Convertible bonds
  • News
    • Press Releases
      • 2025
      • 2024
      • 2023
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
    • Biophytis in Media
  • Recruitment
  • Contact
    • Contact
    • Contact Information
    • Legal information
  • LinkedIn
  • Twitter
  • FR
  • EN

Author Archives: Antoine

JANUARY 10, 2020

Press ReleasesBy Antoine10 January 2020

Biophytis announces the issuance of a €3 million tranche of ORNANEBSA. Read the Press Release

JANUARY 2, 2020

Press ReleasesBy Antoine2 January 2020

Biophytis has appointed Evelyne Nguyen as CFO and Strengthens Senior Management Team. Read the Press Release

December 16, 2019

Press ReleasesBy Antoine16 December 2019

Biophytis Receives FDA Approval to Proceed with the MYODA Program for Clinical Development of Sarconeos (BIO101) in Patients with Duchenne Muscular Dystrophy (DMD). Read the Press Release

December 12, 2019

Press ReleasesBy Antoine12 December 2019

Biophytis to attend Biotech Showcase™ 2020 in San Francisco, USA. Read the Press Release

December 9, 2019

Press ReleasesBy Antoine9 December 2019

Biophytis Presents Preliminary Analysis of SARA-OBS study at the 12th Annual Congress of The Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD) in Berlin, Germany. Read the Press Release

DECEMBER 4, 2019

Press ReleasesBy Antoine4 December 2019

Biophytis to attend 11th Geneva MidCap Event. Read the Press Release

NOVEMBER 18, 2019

Press ReleasesBy Antoine18 November 2019

Biophytis to participate in the 6th China Healthcare Summit organized by BioCentury and BayHelix in Shanghai. Read the Press Release

November 15, 2019

Press ReleasesBy Antoine15 November 2019

Biophytis Files IND Application with FDA for Sarconeos (BIO101) to Support Planned MYODA Clinical Program in Patients with DMD. Read the Press Release

NOVEMBER 7, 2019

Press ReleasesBy Antoine7 November 2019

Biophytis to attend BIO-Europe® in Hamburg. Read the Press Release

OCTOBER 31, 2019

Press ReleasesBy Antoine31 October 2019

Biophytis Files Protocol Amendment to Optimize the SARA-INT Phase 2b Clinical Trial for Sarcopenia.  Read the Press Release

←1
2345678910111213141516171819
…2021222324…
25262728293031323334
35→
© Biophytis 2006-2025 - Mentions Légales
  • Corporate
    • Executive Committee
    • Scientific Advisory Board
    • Boards of Directors
    • Code of Ethics
Footer Colonne 1 - Anglais
Go to Top
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok